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Background/aim: Nosocomial bloodstream infection (BSI) increases mortality rates, duration of stay in hospital, and treatment costs.
This study was conducted to determine the rate and the risk factors of BSIs among intensive care unit patients.
Materials and methods: Sixty-four patients with BSIs (patient group) and 79 patients without a nosocomial infection (control group)
were enrolled in the study. Centers for Disease Control and Prevention criteria were used for diagnosing BSIs. Potential risk factors were
evaluated by multivariate logistic regression model.
Results: The BSI development rate was 15.7% (64/407), with an incidence rate of 18.2/1000 patient days. Distribution of pathogens
among BSI patients were as follows: gram-positive cocci, 42.18% (27/64); gram-negative cocci, 34.3% (22/64); and Candida spp., 23.4%
(15/64). Risk factors were determined as intubation, arterial catheter, tracheostomy, duration of intubation, duration of catheter use,
duration of nasogastric catheter, underlying diseases of chronic renal failure and diabetes mellitus, implemented treatments of sedation
and enteral nutrition, and APACHE II score.
Conclusion: BSIs are the leading cause of mortality and morbidity in intensive care unit patients. Determination of the local risk factors
is important and necessary for decreasing the rate of BSIs and the mortality rates.
Key words: Bloodstream infection, candidemia, intensive care unit

1. Introduction
Nosocomial infections are important public health
problems in both developing and developed countries (1).
The rate of nosocomial infections among intensive care
unit (ICU) patients is 5- to 10-fold greater than in patients
of other clinics (2). The most frequent types of nosocomial
infections are urinary tract infection, surgical wound
infection, pneumonia, and bloodstream infection (BSI)
(3). Nosocomial BSI increases mortality rates, duration
of stay in hospital, and treatment costs. Development of
nosocomial BSI in ICUs leads to a duration of 24 additional
days of stay in the hospital and an additional treatment
cost of 40,000 US$ (2). The objective of this study was to
determine the pathogenic agents causing nosocomial BSIs
and the risk factors that play a role in the development of
BSIs among patients followed in a central intensive care
unit (CICU).
2. Materials and methods
This study was conducted in the Gaziantep University
Medical Faculty’s CICU during a 6-month period in 2011.
It was approved by the Ethics Committee of the Gaziantep
* Correspondence: ayseozlem_ornek@hotmail.com

University Medical Faculty (05/20113). During the study
period, patients hospitalized in CICU were followed on a
daily basis and findings were recorded on a daily follow-up
form specifically prepared for this study.
2.1. Subjects
Patients with a laboratory and clinical diagnosis of
bloodstream infection followed in the CICU were enrolled
in the study. Patients were not classified as primary or
secondary BSI patients. If more than one BSI episode
developed in same patient, only the first was included.
Diagnosis of BSI was based on criteria issued by the
Centers for Disease Control and Prevention and the
International Sepsis Group (4,5). Patients hospitalized in
the CICU without a diagnosis of nosocomial infection
were designated as the control group.
Patients hospitalized for less than 48 h and those under
16 years of age were excluded. For all subjects, age, sex,
underlying diseases, APACHE II score, duration of stay
in CICU, duration of stay in hospital, invasive procedures
and their durations (tracheostomy, central catheterization,
urinary catheterization, arterial catheterization), and
durations of any implemented treatments (steroid,
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antibiotics, sedation, gastroprotective agents) were
recorded. Procalcitonin levels of all patients were noted
and compared.
2.2. Sampling, microbiological evaluation, and
identification
Blood cultures were assessed in a BacT/Alert automated
blood culture system. Blood culture samples with positive
signals were processed. Subcultures were prepared on
eosin-methylene-blue and sheep blood agar 5% media.
The identification and antibiograms of growing bacteria
were determined with the VITEK 2 (BioMerieux, France)
fully automated identification and antibiogram system.
Production of expanded-spectrum beta lactamase (ESBL)
by E. coli and Klebsiella spp. was assessed with the VITEK
2 ESBL test panels.
2.3. Statistical analysis
Statistical analysis was performed with SPSS 16.0 (SPSS
Inc., USA). Correlation between categorical variables
was evaluated by chi-square test and/or Fisher’s exact
test. For quantitative variables with normal distribution,
significance of comparison of means in 2 groups was
realized by Student’s t-test. Means were assessed by
standard deviation. In all tests, the minimum limit of
significance was determined as 0.05 (P < 0.05). A further
test of binary logistic regression analysis was implemented
for independent risk factors. Based on findings of this
analysis, odds ratios (ORs) were calculated.
3. Results
During the study period, a total of 407 patients were
admitted to the CICU. Nosocomial infection developed
in 165 (40.54%) of these patients. Among patients with
nosocomial infections, 64 (15.7%) were diagnosed with
BSI. The incidence rate of BSI was calculated as 18.2/1000.
3.1. Comparison of patients diagnosed with BSI
Patients with BSIs were compared with the control group
by bivariate analysis. Total stay in CICU, duration of stay in
hospital prior to admission to CICU, underlying diseases
of chronic renal failure (CRF) and diabetes mellitus
(DM), and, among invasive procedures, intubation, use
of arterial catheter, and tracheostomy were observed to be
significantly higher in patients with BSIs (Table 1). Mean
durations of intubation, urinary catheter, nasogastric
catheter, and central venous catheter (CVC) were longer in
patients with BSIs and a statistically significant correlation
was found between these parameters and development
of BSIs. Sedation (P = 0.039) and enteral nutrition (P =
0.016) were found to be more common among the BSI
group. Forty-seven of 64 patients with BSIs (73.4%) and
28 of 79 control patients (35.4%) died during their stays in
the ICU. Mortality in the BSI group was determined to be
significantly higher (P = 0.000) (Table 1).
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Procalcitonin values were determined as 8.13 ± 17.48
ng/mL in the BSI group and 5.69 ± 16.62 ng/mL in the
control group. The difference between the groups was
not statistically significant (P = 0.264) (Table 1). The
mean procalcitonin value of all subjects (control group
and patient group) was 6.8 ng/mL. Among patients with
procalcitonin values of <6.8 ng/mL, the mortality rate
was 39.7%, while this rate was 66.7% in patients with
procalcitonin values of >6.8 ng/mL (Table 2).
Mean APACHE II score was 21.33 ± 6.17 in the
BSI group and 13.39 ± 16.67 in the control group. This
difference was statistically significant (P = 0.001). Mean
APACHE II score of all subjects (control group and
patient group) was 17. The mortality rate of patients with
APACHE II score of <17 was 29.2%, while this rate was
71.2% in patients with APACHE II score of >17 (Table 2).
3.2. Distribution of pathogenic microorganisms
Gram-positive bacteremia was determined in 27
(42.1%) of BSI patients. Of these isolates, 21 (32.8%)
were staphylococci and 6 (9.3%) were Enterococcus spp.
Among staphylococci, 85% were coagulase-negative.
The identification of staphylococci types revealed S.
haemolyticus in 6 (9.3%) patients, S. hominis in 7 (7%),
S. epidermidis in 5 (7.8%), and S. aureus in 3 (4.6%).
Distribution of gram-negative bacteria was as follows:
12 (18.75%) cases of Acinetobacter spp., 2 (3.1%)
Pseudomonas spp., 3 (4.6%) Klebsiella spp. and 5 (7.8%)
E. coli. Fifteen (23.4%) samples of Candida spp. were
isolated and the types were determined as Candida
albicans in 6 patients (40%) and nonalbicans Candida in
9 (60%) patients (Table 3).
3.3. Comparison of patients with candidemia
In candidemia patients as compared with the control
group, age, duration of stay in the CICU, duration of stay
in the hospital prior to the CICU, presence of CRF and
DM, rate of intubation, rate of arterial catheter use, rate of
tracheostomy, duration of CVC, mean duration of urinary
catheter use, rate of enteral nutrition, rate of mortality,
and mean APACHE II score were found to be statistically
significant in terms of development of candidemia (Table
4). The number of antibiotic agents used in patients with
candidemia was significantly higher than in the control
group.
3.4. Logistic regression analysis in development of
candidemia
Risk factors of CRF, DM, and coexistence of CRF and DM,
determined significant at P < 0.05 by bivariate statistical
analysis method, were evaluated in a binary logistic
regression model. As per this assessment, the presence
of CRF increased the risk of candidemia by 4.9-fold,
the presence of DM caused an increase of 3.6-fold, and
coexistence of CRF and DM elevated the risk by 9.3-fold
(Table 5).
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Table 1. Comparison of patient and control groups.
Patient group

Control group

P

37/27

38/41

0.248

Age

58.19 ± 19.40

53.27 ± 19.79

0.138

Duration of stay in CICU

21.95 ± 16.37

8.71 ± 6.21

0.001

Duration of stay in hosp. prior to CICU

11.42 ± 7.15

6.5 ± 5.57

0.001

APACHE II score

21.33 ± 6.17

13.39 ± 6.67

0.001

CRF

23 (35.9)

12 (15.2)

0.004

DM

26 (40.6)

15 (19.0)

0.004

7 (10.9)

9 (11.4)

0.932

Sex

M/F (75/68)

Underlying diseases

COPD
Liver cirrhosis

4 (6.3)

12 (15.2)

0.092

10 (15.6)

14 (17.7)

0.739

CVC

57 (89.6)

70 (88.6)

0.932

Intubation

57 (89.1)

32 (40.6)

0.000

AC

49 (76.6)

46 (58.2)

0.021

NG

44 (68.5)

47 (59.5)

0.253

Tracheostomy

21 (32.8)

3 (3.8)

0.000

11.34 ± 4.21

7.54 ± 4.61

0.000

Intubation days

9.30 ± 6.11

6.34 ± 4.09

0.021

AC days

7.78 ± 4.03

6.48 ± 3.10

0.084

NG days

8.77 ± 4.48

6.35 ± 3.39

0.004

UC days

9.86 ± 3.79

7.06 ± 3.83

0.001

Malignity
Rate of invasive procedures

Duration of invasive procedures
CVC days

Implemented treatments
Sedation

37 (57.8)

32 (40.05)

0.039

Steroid treatment

28 (43.8)

30 (37.98)

0.484

Enteral nutrition

34 (64.2)

24 (30.40)

0.016

Mortality rates

47 (73.4)

28 (35.4)

0.000

Procalcitonin

8.13 ± 17.48

5.69 ± 16.62

0.264

History of surgery

14 (21.9)

16 (20.3)

0.813

AC: Arterial catheterization, UC: urinary catheterization, NG: nasogastric catheter, CVC: central venous
catheter, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus, CRF: chronic renal failure.

4. Discussion
Nosocomial infections are one of the leading causes
of mortality and morbidity, particularly in critically ill
patients. The nosocomial infection rate is estimated as 2%,
and this rate can increase to up to 54% in patients staying
in ICUs (6). Nosocomial BSIs extend the time of stay and
increase the mortality risk and the cost of treatment.
In the current study, BSIs developed in 64/407 (15.7%)
of the patients, while the incidence rate was determined
as 18.2 per patient days (18.2/1000). In a multicenter
study conducted in Turkey at 12 hospitals (including 11

university hospitals) among members of the International
Nosocomial Infection Control Consortium from 10 cities,
the mean rate of device-associated hospital acquired
infections for a 3-year period was determined as 33.9
per 1000 patient days. Rate of bloodstream infections
associated with CVCs was 19.6 (5.3/1000 to 41.5/1000) per
1000 catheter days. These rates are similar to our results
(7).
Another risk factor that was determined for
development of BSIs is arterial catheterization. Duration
of catheterization, frequent manipulation of catheter,
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Table 2. Correlation of APACHE II scores and procalcitonin values with mortality.

APACHE II

Procalcitonin

Result

≤17

>17

Exitus

23 (29.2%)

47 (71.2%)

Recovered

56 (70.8%)

19 (28.8%)

≤6.8 ng/mL

>6.8 ng/mL

Exitus

48 (39.7%)

18 (66.7%)

Recovered

70 (60.3%)

9 (33.3%)

P
0.000

0.011

Table 3. Distribution of agent pathogen microorganisms in patients with BSIs.
Agent microorganism

Gram-positive

Gram-negative

Candida

%

S. hominis

7

10.9

S. haemolyticus

6

9.3

S. epidermidis

5

7.8

S. aureus

3

Enterococcus spp.

6

4.6
9.3

Acinetobacter spp.

12

18.7

E. coli

5

7.8

Pseudomonas spp.

2

Klebsiella spp.

3

3.1
4.6

C. albicans

6

9.3

Nonalbicans

9

14

location of catheter, type of catheter, underlying diseases,
suppression of immune system, and types of fluids
administered through the catheter are significant risk
factors in development of BSIs (8). The correlation
between development of BSIs and use of arterial catheters
in our study was found to be statistically significant. Use
of arterial catheters is not a routine procedure during
monitoring in ICUs; the procedure is performed in
cases of increased requirements for vasopressors. Since
arterial catheters are generally applied under emergency
conditions, the required aseptic conditions may not have
been provided.
Intubation was assessed as a risk factor for development
of BSIs in our study. The following mechanisms are
responsible for this. Endotracheal intubation disturbs
defense mechanisms of the host and cough and mucociliary
activity; also, during mechanical ventilation in particular,
this condition is more prominent in the development
of ventilation-associated pneumonia (9). Prolonged
duration of intubation and respiratory failure increases
the rate of acquired infections in ICUs and, as a result,
secondary bacteremia can develop (9–12). In our hospital,
tracheostomy is performed after the 10th day and causes
prolongation of hospital stay; the presence of tracheostomy

1246

n = 64

may also be a risk factor for primary bacteremia (13).
Therefore, the relation between tracheostomy and BSI is
thought to be a result of both of these factors.
It is known that the risk of infection associated with
bacterial translocation secondary to intestinal mucosal
atrophy is increased with parenteral nutrition. It is
recommended to switch patients to enteral nutrition as early
as possible. However, enteral nutrition was determined as a
risk factor for development of BSIs in this study. Similarly,
enteral nutrition in the ICU was designated as a risk factor
for development of BSIs in various studies (14,15). Usually
for enteral nutrition, nasogastric tubes are used in the
ICU. It is thought that colonization of the tube results in
bacteremia (15). In our study, not the use of nasogastric
tube but rather the duration of nasogastric tube was found
to be significant as a risk factor for BSIs.
Sedation was also specified as a risk factor for BSIs. A
3.34-fold increase was reported in nosocomial infections
among sedated patients (16). In a similar study, sedative
medication was determined to increase the risk of
nosocomial infections in the ICU (17). In patients with
suppressed swallow reflex due to sedation, development
of aspiration and associated pneumonia may increase the
risk of secondary BSIs.

SÜNER et al. / Turk J Med Sci
Table 4. Comparison of patients with candidemia and control group.

Sex

M/F (48/46)

Age

Candidemia

Control group

P

10/5

38/41

0.138

56.53 ± 22.66

53.27 ± 19.79

0.000

Duration of stay in CICU

21.20 ± 4.67

8.71 ± 6.21

0.005

Duration of hosp. prior to CICU

17.27 ± 7.73

6.40 ± 5.54

0.001

APACHE II score

22.73 ± 6.15

13.39 ± 6.67

0.001

CRF

8 (53.3)

12 (15.2)

0.015

DM

8 (53.3)

15 (19.0)

0.004

Underlying diseases

COPD

1(11.4)

9 (11.4)

0.586

Liver cirrhosis

0 (0)

12 (15.2)

2 (13.3)

14 (17.0)

0.106
0.678

CVC

14 (93.3)

70 (88.6)

0.586

Intubation

14 (93.3)

32 (38.3)

0.000

AC

13 (86.7)

46 (58.2)

0.006

NG

8 (53.3)

47 (59.5)

Tracheostomy

5 (33.3)

3 (3.8)

0.657
0.000

11.64 ± 4.37

7.54 ± 4.21

0.001

Intubation days

9.71 ± 6.46

6.34 ± 4.09

0.091

AC days

7.78 ± 4.80

6.43 ± 3.09

0.060

NG days

10.13 ± 4.25

6.21 ± 3.38

UC days

9.93 ± 3.84

7.06 ± 3.83

0.005
0.009

Malignity
Rate of invasive procedures

Duration of invasive procedures
CVC days

Implemented treatments
Sedation
Enteral nutrition

5 (33.3)

32 (40.05)

0.062

9 (60)

24 (30.40)

0.028

Mortality rates

15 (100)

28 (35.4)

0.000

Procalcitonin

9.04 ± 9.34

5.69 ± 16.62

0.454

AC: Arterial catheterization, UC: urinary catheterization, NG: nasogastric catheter, CVC: central
venous catheter, COPD: chronic obstructive pulmonary disease, DM: diabetes mellitus, CRF:
chronic renal failure.

It was determined that prolonged stay in the ICU
increases the risk of infection (16–19). In the current
study, prolonged duration of stay in the ICU was found
as a risk factor for development of BSIs. Mean duration of
stay was determined as 21.95 ± 7.15 days in the BSI group
and 8.71 ± 6.21 days in the control group. Evaluation of
mean duration of hospitalization prior to admission to the
ICU revealed prolonged duration of hospitalization as a
risk factor for BSIs. During long hospitalizations, patients
are more frequently exposed to nosocomial pathogens and
development of nosocomial infections is thought to be

associated with increased colonization. ICU stays of 3–4
days increase the risk of infection by 3-fold as compared to
stays of 1–2 days (20). This period was determined as 11 ±
6.72 days in our study. The BSI development period from
admission to the ICU was reported as 12 days and 11.5 ±
5.7 days in 2 different studies (21,22).
A significant correlation exists between APACHE II
score and mortality (16,19). Invasive procedures are more
frequently performed in patients with high APACHE II
scores during their stay in ICUs; increased numbers of
invasive procedures and longer stays in the hospital in
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Table 5. Risk factors for candidemia in logistic regression analysis.
P

OR

Lower limit

Upper limit

DM

0.009

3.601

1.049

12.360

CRF

0.012

4.937

1.429

17.051

CRF and DM

0.003

9.375

2.153

40.817

patients with high APACHE II scores may lead to higher
rates of BSIs in this patient group. In the current trial,
high APACHE II score was determined as a risk factor
for development of BSIs. Similarly, the rate of mortality
was significantly higher in patients with high APACHE II
scores.
For the time being, nosocomial BSIs are infectious
diseases with the highest mortality rate, despite significant
improvements in medical technology and antimicrobial
treatment. Trials conducted on this topic indicate crude
mortality rates associated with BSIs of 12%–80%, with
a mean rate of 35%. The rate of mortality related to
infection was reported as 27% (23,24). In the current
study, development of BSI was determined to increase the
mortality rate. A significant correlation was found between
BSI and mortality (17,25). Development of such a disease
in ICU patients with poor general medical condition, high
APACHE scores, and comorbidities, caused by resistant
microorganisms, will definitely lead to a poorer outcome.
In a metaanalysis covering 12 studies comparing
procalcitonin and C-reactive protein levels, procalcitonin
was reported to be more beneficial than C-reactive protein
in terms of differentiation of bacterial infections from
other noninfectious systemic inflammatory responses
(26). In the current study, procalcitonin levels of patients
with BSIs did not reveal a significant difference compared
to controls; however, a direct correlation was determined
between high procalcitonin values and mortality.
Distributions of the microorganisms isolated as agent
pathogens in a similar study were P. aeruginosa at 20.8%,
Staphylococcus aureus at 18.2%, Acinetobacter spp. at
18.2%, and Klebsiella spp. at 16.1% (15). The distributions
in our study were as follows: staphylococci at 32.8%,
Enterococcus spp. at 9.3%, Acinetobacter spp. at 18.7%, P.
aeruginosa at 4.6%, Klebsiella spp. at 4.6%, E. coli at 7.8%,
and Candida spp. at 23.4%. In our study, gram-positive
agents were more frequent, and another remarkable result
is the high candidemia rates. In recent years, a significant
increase has been seen in systemic mycoses cases in ICUs,
with trials conducted in Europe and the United States
indicating that fungi infections, and mainly Candida
infections, have the highest mortality rates (27). In the
current study, 6 of the Candida samples specified as agent
pathogens of BSIs (40%) were determined as Candida
albicans and 9 (60%) were specified as nonalbicans
Candida. Nonalbicans Candida included C. parapsilosis (n
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= 3), C. glabrata (n = 2), C. tropicalis (n = 2), C. krusei (n
= 1), and C. lusitaniae (n = 1). In a study performed in the
United States investigating the national epidemiology of
mycoses, Candida species similarly ranked fourth among
the most common causes of hospital-acquired BSIs in 7
surgical ICUs and 6 newborn ICUs, and species-based
distribution of Candida was determined as C. albicans at
48%, C. glabrata at 24%, C. tropicalis at 19%, C. parapsilosis
at 7%, and other species at 2% (28). In a similar study, 49%
of 74 strains isolated from blood cultures were designated
as C. albicans, 23% as C. parapsilosis, 14% as C. tropica
lis, 12% as C. glabrata, 1% as C. guilliermondii, and 1% as
C. krusei (29). In our study, Candida ranked third among
agent pathogens. No azole resistance was found among
Candida species in the current study. Only in C. krusei
was decreased sensitivity determined against fluconazole.
Resistance against azoles in C. glabrata and C. krusei is
found to increase due to the increase of candidemia rates
and the use of azoles (30).
Assessment of underlying diseases in patients with
candidemia indicated the presences of CRF and DM
as risk factors (31,32). In different studies, invasive
procedures, duration of invasive procedures, duration of
stay in hospital, immunosuppressive treatment, and longterm use of antibiotics were regarded as risk factors for
candidemia (33–35). In the current study, use of arterial
catheters, enteral nutrition, intubation, tracheostomy,
duration of CVC use, duration of urinary catheter use,
high APACHE II score, duration of stay in CICU, duration
of hospitalization prior to admission to CICU, and
underlying DM and CRF were designated as risk factors
for development of candidemia. The duration as well as
presence of invasive procedures were also determined
as risk factors. Among implemented treatments, enteral
nutrition was determined as a risk factor for development
of candidemia.
BSIs detected in ICUs have high mortality and morbidity
rates. Today BSIs remain associated with microorganisms
that are resistant to antibiotics and can easily be spread
by hospital personnel (36). Being informed about the risk
factors associated with BSIs in this patient group will create
consciousness among health care providers and physicians
in terms of approaches to the patients and conventional
behavior models. The goal of determining the risk factors
of BSIs is to decrease infection rates and thus decrease the
mortality associated with BSIs.
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